Companies /Healthcare

Amarin Corp

NASDAQ: AMRN Drug Manufacturers - General
$14.07
▼ $0.31 (−2.12%) today
Markets closed · 11:13pm ET

AMRN Coverage

Page 2
11:33am ET
Health and Healthcare

Is Amarin Stock Poised for a Strong Recovery?

Amarin has been right in the middle of this recent market sell-off, and while shares have been halved, the stock could be poised for a strong recovery. All the pieces seem to…

Chris Lange
12:40pm ET
Health and Healthcare

Amarin Stock Faces Sell-Off Crisis

Shares of Amarin have plunged in recent months. Even more troubling, there appears to no catalyst to drive them higher.

Douglas A. McIntyre
1:05pm ET
Health and Healthcare

When Will Amarin Stock Sell-Off Be Over?

Amarin is a development-stage biotechnology company with one FDA-approved treatment, a cardiovascular disease drug with no real competition. The company looks well-poised to boost sales in 2020 and going forward.

Douglas A. McIntyre
10:50am ET
Health and Healthcare

Is Amarin’s Cardio Trial in Trouble?

Amarin shares dropped on Friday after the firm announced that it received notice from the FDA that delays a pending supplemental new drug application.

Chris Lange
10:20am ET
Health and Healthcare

Tuesday’s Biggest Biotech Movers

24/7 Wall St. has picked a few of those standouts from Tuesday to highlight. We have included information about each company, as well as recent trading activity and the consensus analyst price…

Chris Lange